HC Wainwright Analysts Reduce Earnings Estimates for DAWN

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – HC Wainwright decreased their Q2 2025 earnings per share estimates for Day One Biopharmaceuticals in a report released on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.32) for the quarter, down from their previous estimate of ($0.30). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($0.34) EPS and FY2027 earnings at $0.58 EPS.

DAWN has been the subject of several other research reports. Needham & Company LLC lowered their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday. The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, March 25th. Finally, JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $30.57.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $6.45 on Friday. The stock has a 50 day moving average price of $7.70 and a two-hundred day moving average price of $11.08. Day One Biopharmaceuticals has a 52 week low of $6.26 and a 52 week high of $17.14. The firm has a market capitalization of $653.78 million, a P/E ratio of -6.26 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DAWN. GF Fund Management CO. LTD. purchased a new stake in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $27,000. R Squared Ltd bought a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $31,000. Pallas Capital Advisors LLC purchased a new position in shares of Day One Biopharmaceuticals in the 1st quarter worth $87,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Day One Biopharmaceuticals during the 1st quarter valued at about $88,000. Finally, Exchange Traded Concepts LLC increased its holdings in Day One Biopharmaceuticals by 19.6% during the first quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company’s stock valued at $117,000 after buying an additional 2,407 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock valued at $251,925 over the last three months. Insiders own 6.20% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.